Dose-intensity temozolomide after concurrent chemoradiotherapy in operated high-grade gliomas

Journal of Neuro-Oncology

Volumn 90, Issue 3, 2008, Pages 315-319

  Dall'Oglio, Stefano ^a   D'Amico, Anna ^a   Pioli, Fabio ^a   Gabbani, Milena ^a   Pasini, Felice ^a   Passarin, Maria Grazia ^a   Talacchi, Andrea ^a   Turazzi, Sergio ^a   Maluta, Sergio ^a  

^a UNIVERSITY HOSPITAL OF VERONA   (Italy)

Author keywords

Dose intensity; High grade gliomas; Radiotherapy; Temozolomide

Indexed keywords

TEMOZOLOMIDE;

ADULT; ADVERSE OUTCOME; AGED; ANEMIA; ARTICLE; CANCER CHEMOTHERAPY; CANCER GRADING; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; CLINICAL TRIAL; DISEASE FREE SURVIVAL; DOSE RESPONSE; DRUG DOSE ESCALATION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG WITHDRAWAL; FEMALE; GLIOBLASTOMA; GLIOMA; HUMAN; LYMPHOCYTOPENIA; MALE; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PATIENT MONITORING; PHASE 2 CLINICAL TRIAL; PNEUMOCYSTIS PNEUMONIA; RADIATION DOSE FRACTIONATION; SURVIVAL RATE; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC AGENTS, ALKYLATING; BRAIN NEOPLASMS; DACARBAZINE; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FOLLOW-UP STUDIES; GLIOMA; HUMANS; KAPLAN-MEIERS ESTIMATE; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES;

EID: 56249136872     PISSN: 0167594X     EISSN: 15737373     Source Type: Journal    
DOI: 10.1007/s11060-008-9663-9     Document Type: Article

References (14)

1. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ et al (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987-996. doi: 10.1056/NEJMoa043330
2. Wick A, Felsberg J, Steinbach JP, Herrlinger U, Platten M, Blaschke B et al (2007) Efficacy and tolerability of temozolomide in an alternating weekly regimen in patients with recurrent glioma. J Clin Oncol 25:3357-3361. doi: 10.1200/JCO.2007.10.7722
3. Tolcher AW, Gerson SL, Denis L, Geyer C, Hammond LA, Patnaik A et al (2003) Marked inactivation of O6-alkylguanine-DNA alkyltransferase activity with protracted temozolomide schedules. Br J Cancer 88:1004-1011. doi: 10.1038/sj.bjc.6600827
4. Wick W, Weller M (2005) How lymphotoxic is dose-intensified temozolomide? The glioblastoma experience. J Clin Oncol 23:4235-4236
5. Scott CB, Scarantino C, Urtasun R, Movsas B, Jones CU, Simpson JR et al (1998) Validation and predictive power of Radiation Therapy Oncology Group (RTOG) recursive partitioning analysis classes for malignant glioma patients: A report using RTOG 90-06. Int J Radiat Oncol Biol Phys 40:51-55. doi: 10.1016/S0360-3016(97)00485-9
6. Cahill DP, Levine KK, Betensky RA, Codd PJ, Romany CA, Reavie LB et al (2007) Loss of the mismatch repair protein MSH6 in human glioblastomas is associated with tumor progression during temozolomide treatment. Clin Cancer Res 13:2038-2045. doi: 10.1158/1078-0432.CCR-06-2149
7. Neyns B, van Mierlo B, Menten J, Dhondt L, Joosens E, Vastesaeger N et al (2005) A phase II study of temozolomide administered 21 out of 28 days for the treatment of patients with recurrent anaplastic (oligo) astrocytoma: An interim analysis of toxicity. J Clin Oncol 23:1560 Meeting abstracts
8. Tosoni A, Franceschi E, Ermani M, Bertorelle R, Bonaldi L, Blatt V, Brandes AA (2008) Temozolomide three weeks on and one week off as first line therapy for patients with recurrent or progressive low grade gliomas. J Neurooncol [Epub ahead of print]
9. Wong ET, Hess KR, Gleason MJ, Jaeckle KA, Kyritsis AP, Prados MD et al (1999) Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials. J Clin Oncol 17:2572-2578
10. Soffietti R, Rudà R (2008) Neuro-oncology: New insights and advances in treatment. Lancet Neurol 7:14-16. doi: 10.1016/ S1474-4422(07)70305-8
11. Baruchel S, Diezi M, Hargrave D, Stempak D, Gammon J, Moghrabi A et al (2006) Safety and pharmacokinetics of temozolomide using a dose-escalation, metronomic schedule in recurrent paediatric brain tumours. Eur J Cancer 42:2335-2342. doi: 10.1016/j.ejca.2006.03.023
12. Brada M, Judson I, Beale P, Moore S, Reidenberg P, Statkevich P et al (1999) Phase I dose-escalation and pharmacokinetic study of temozolomide (SCH 52365) for refractory or relapsing malignancies. Br J Cancer 81:1022-1030. doi: 10.1038/sj.bjc.6690802
13. Chinot OL, Barrié M, Fuentes S, Eudes N, Lancelot S, Metellus P et al (2007) Correlation between O6-methylguanine-DNA methyltransferase and survival in inoperable newly diagnosed glioblastoma patients treated with neoadjuvant temozolomide. J Clin Oncol 25:1459-1460. doi: 10.1200/ JCO.2006.07.4807
14. Brandes AA, Tosoni A, Cavallo G, Bertorelle R, Gioia V, Franceschi E et al (2006) Temozolomide 3 weeks on and 1 week off as first-line therapy for recurrent glioblastoma: Phase II study from Gruppo Italiano Cooperativo di Neuro-oncologia (GICNO). Br J Cancer 95:1155-1160. doi: 10.1038/sj.bjc.6603376